LAVA Therapeutics NV [NASDAQ: LVTX] closed the trading session at $2.25. The company report on March 5, 2024 at 7:30 AM that LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223).
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023.
The stocks have a year to date performance of 42.41 percent and weekly performance of 6.13 percent. The stock has been moved at 26.40 percent over the last six months. The stock has performed 30.81 percent around the most recent 30 days and changed 50.00 percent over the most recent 3-months.
If compared to the average trading volume of 1.55M shares, LVTX reached to a volume of 8910261 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about LAVA Therapeutics NV [LVTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LVTX shares is $6.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LVTX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for LAVA Therapeutics NV shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 25, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Outperform. The new note on the price target was released on April 19, 2021, representing the official price target for LAVA Therapeutics NV stock. Previously, the target price had yet another raise to $22, while JP Morgan analysts kept a Overweight rating on LVTX stock.
The Average True Range (ATR) for LAVA Therapeutics NV is set at 0.64, with the Price to Sales ratio for LVTX stock in the period of the last 12 months amounting to 6.53. The Price to Book ratio for the last quarter was 1.08, with the Price to Cash per share for the same quarter was set at 3.98.
LVTX stock trade performance evaluation
LAVA Therapeutics NV [LVTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.13. With this latest performance, LVTX shares gained by 30.81% in over the last four-week period, additionally plugging by 26.40% over the last 6 months – not to mention a drop of -7.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LVTX stock in for the last two-week period is set at 52.10, with the RSI for the last a single of trading hit 50.41, and the three-weeks RSI is set at 53.02 for LAVA Therapeutics NV [LVTX]. The present Moving Average for the last 50 days of trading for this stock 1.84, while it was recorded at 2.59 for the last single week of trading, and 1.74 for the last 200 days.
LAVA Therapeutics NV [LVTX]: An insightful look at the core fundamentals
LAVA Therapeutics NV’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.20.
Earnings per share (EPS) analysis for LAVA Therapeutics NV [LVTX] stock
With the latest financial reports released by the company, LAVA Therapeutics NV posted -0.57/share EPS, while the average EPS was predicted by analysts to be reported at -0.64/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LVTX.
LAVA Therapeutics NV [LVTX]: Institutional Ownership
The top three institutional holders of LVTX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in LVTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in LVTX stock with ownership which is approximately 5.8325%.
